Sara L.
- Country
- Italy
- Department
- Unità di Oncologia Medica 1
Research Overview
- Evaluation of Safety and Efficacy of Targeted Therapies in Metastatic Colorectal Cancer Subpopulations
- A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)
- A Randomized, Open-label, Phase 2 study of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) or Investigator’s Choice Standard of Care (Regorafenib or Trifluridine and Tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer
Data & Insights
Has run more than one trial at 348 of 616 partner sites.
Specializations
Colorectal Cancer Research
The investigator specializes in advanced therapeutic approaches for metastatic colorectal cancer, with particular focus on BRAF V600E mutations and microsatellite stability status.
- Targeted Therapy Combinations
- Treatment Sequencing Strategies
- Biomarker-Driven Approaches
Their research extends to novel treatment strategies for both early-stage and advanced disease, including circulating tumor DNA-guided therapy.
Gastrointestinal Oncology
The investigator conducts research in various gastrointestinal cancers, including pancreatic ductal adenocarcinoma and esophageal carcinoma.
- Neoadjuvant Treatment Strategies
- Immunotherapy Applications
- Multi-Modal Treatment Approaches
Their work encompasses both conventional and innovative therapeutic strategies for locally advanced and metastatic disease.
Precision Medicine
The investigator focuses on biomarker-driven treatment selection and personalized therapy approaches in gastrointestinal cancers.
- Molecular Profiling
- Targeted Therapy Development
- Treatment Response Monitoring
Their research emphasizes the integration of molecular diagnostics with therapeutic decision-making.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.